Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994314 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2994310 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6572673 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5304089 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6574468 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7349039 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6574444 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6574466 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7343838 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL7343843 | 1.00 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128284-A1 | Tropane-derivatives, their preparation and use | NEUROSEARCH A/S | 2002-09-12 | — | — | US | disclosed |
| EP-0756596-B1 | TROPANE-2-ALDOXIME DERIVATIVES AS NEUROTRANSMITTER REUPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2002-08-21 | — | — | EP | disclosed |
| US-6288079-B1 | MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS; NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, SLEEP, AND BRAIN DISORDERS; ALZHEIMER*S AND PARKINSON*S DISEASE; TESOFENSINE (2-ethoxymethyl-3-(3,4-dichlorophenyl)-tropane) | NEUROSEARCH A/S (DK) | 2001-09-11 | — | — | US | disclosed |
| EP-1130020-A1 | Tropane-derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2001-09-05 | — | — | EP | disclosed |
| EP-0885220-B1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2001-07-11 | — | — | EP | disclosed |
| US-5736556-A | PARKINSON*S DISEASE; ANTIDEPRESSANTS; ANTIOBESITY; ANTINARCOLEPSY; DRUG ABRUSE | NEUROSEARCH A/S (DK) | 1998-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128284-A1 | Tropane-derivatives, their preparation and use | ADRB3, ADRB2, ADRA2C | SLC6A3 11/4885SLC6A4 60/4885SLC6A2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.